ETHZilla (ETHZ) Stock Overview
A clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ETHZ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ETHZilla Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.37 |
| 52 Week High | US$17.75 |
| 52 Week Low | US$0.66 |
| Beta | 0.39 |
| 1 Month Change | -66.34% |
| 3 Month Change | 155.11% |
| 1 Year Change | 29.51% |
| 3 Year Change | -99.17% |
| 5 Year Change | -99.94% |
| Change since IPO | -99.94% |
Recent News & Updates
Shareholder Returns
| ETHZ | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.9% | -1.6% | 1.9% |
| 1Y | 29.5% | -10.2% | 18.9% |
Return vs Industry: ETHZ exceeded the US Biotechs industry which returned -9.4% over the past year.
Return vs Market: ETHZ exceeded the US Market which returned 18.5% over the past year.
Price Volatility
| ETHZ volatility | |
|---|---|
| ETHZ Average Weekly Movement | 70.7% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ETHZ's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ETHZ's weekly volatility has increased from 60% to 71% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 4 | McAndrew Rudisill | www.ethzilla.com |
ETHZilla Corporation, a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain. The company was formerly known as 180 Life Sciences Corp. and changed its name to ETHZilla Corporation in August 2025.
ETHZilla Corporation Fundamentals Summary
| ETHZ fundamental statistics | |
|---|---|
| Market cap | US$419.29m |
| Earnings (TTM) | -US$17.22m |
| Revenue (TTM) | n/a |
Is ETHZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ETHZ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.22m |
| Earnings | -US$17.22m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 26.3% |
How did ETHZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/15 12:30 |
| End of Day Share Price | 2025/09/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ETHZilla Corporation is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Jason McCarthy | Maxim Group |
| Nazibur Rahman | Maxim Group |